Next generation diabetic therapy and drug delivery systems are used to improve the adherence to insulin in diabetic patients to reduce the risk of complications related to sudden change in the blood sugar level. Oral & inhalable insulin painlessly manage the blood glucose level, and is expected to replace the injectable insulins. The use of advanced diabetic systems, such as insulin patches, CGM systems, and artificial pancreas is expected to maintain adherence to medication in diabetic patients and improve the quality of life of diabetic patients. The global next generation diabetes therapy and drug delivery market was valued at $617 million in 2015, and is estimated to reach $9,673 million by 2023, registering a CAGR of 41.1% from 2016 to 2023.
The global next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, indication, end user, and geography. Based on product type, it is classified into inhalable insulin, oral insulin, insulin patches, continuous glucose monitoring (CGM) systems, and artificial pancreas. Based on demographics, it is bifurcated into adult population (>14 years) and child population (?14 years). Based on indication, it is divided into type 1 diabetes and type 2 diabetes. Based on end users, it is categorized into diagnostic/clinic, ICU, and home healthcare. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The market growth is attributed to the rise in the number of diabetic patients globally and the increase in disposable income among these patients. The benefits of using these advanced devices over conventional products, such as painless mode of insulin delivery and improvement in adherence to medication, and rise in the healthcare expenditure are expected to increase the demand for these products, thus fueling the market growth. However, lack of awareness, cost restrains in the developing regions, and less variability in products are expected to hamper the growth.
KEY MARKET BENEFITS
This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to product type, demographic, indication, end user, and geography.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY PLAYERS PROFILED
Johnson & Johnson
Abbott Laboratories
Medtronic, Inc.
Sanofi
Novo Nordisk
MannKind Corporation
Enteris BioPharma
Dexcom, Inc.
Senseonics Holding, Inc.
Medtech
KEY MARKET SEGMENTS
By Product Type
Inhalable Insulin
Oral Insulin
Insulin Patches
CGM Systems
Artificial Pancreas
By Demographic
Adult Population (>14years)
Child Population (?14years)
By Indication
Type 1 Diabetes
Type 2 Diabetes
By End User
Diagnostics/Clinics
ICUs
Home Healthcare
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Republic of South Africa
Saudi Arabia
Rest of LAMEA
The other players of the catheters market include (companies not profiled in the report):
Synertech
Zosano Pharma Corp.
Relmada Therapeutics, Inc.
Eli Lilly and Company
Transdermal Specialties Inc.
